De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Seres Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Seres Therapeutics' is Eric Shaff, benoemd in Jan2019, heeft een ambtstermijn van 5.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.16M, bestaande uit 21.7% salaris en 78.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.096% van de aandelen van het bedrijf, ter waarde $ 138.13K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 8.1 jaar.

Belangrijke informatie

Eric Shaff

Algemeen directeur

US$3.2m

Totale compensatie

Percentage CEO-salaris	21.7%
Dienstverband CEO	5.8yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	5.1yrs
Gemiddelde ambtstermijn bestuur	8.1yrs

Recente managementupdates

Recent updates

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 23

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Jul 13

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

May 08

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27

Seres Therapeutics Molecular Data On SER-109 Looks Good

Oct 04

Seres Therapeutics: Here We Go Again

Sep 09

Analyse CEO-vergoeding

Hoe is Eric Shaff's beloning veranderd ten opzichte van Seres Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$162m
Mar 31 2024	n/a	n/a	-US$83m
Dec 31 2023	US$3m	US$685k	-US$114m
Sep 30 2023	n/a	n/a	-US$141m
Jun 30 2023	n/a	n/a	-US$153m
Mar 31 2023	n/a	n/a	-US$265m
Dec 31 2022	US$4m	US$662k	-US$250m
Sep 30 2022	n/a	n/a	-US$231m
Jun 30 2022	n/a	n/a	-US$103m
Mar 31 2022	n/a	n/a	-US$87m
Dec 31 2021	US$10m	US$625k	-US$66m
Sep 30 2021	n/a	n/a	-US$34m
Jun 30 2021	n/a	n/a	-US$132m
Mar 31 2021	n/a	n/a	-US$105m
Dec 31 2020	US$3m	US$590k	-US$89m
Sep 30 2020	n/a	n/a	-US$90m
Jun 30 2020	n/a	n/a	-US$76m
Mar 31 2020	n/a	n/a	-US$66m
Dec 31 2019	US$2m	US$540k	-US$70m
Sep 30 2019	n/a	n/a	-US$73m
Jun 30 2019	n/a	n/a	-US$78m
Mar 31 2019	n/a	n/a	-US$95m
Dec 31 2018	US$1m	US$435k	-US$99m
Sep 30 2018	n/a	n/a	-US$107m
Jun 30 2018	n/a	n/a	-US$92m
Mar 31 2018	n/a	n/a	-US$92m
Dec 31 2017	US$2m	US$377k	-US$89m

Compensatie versus markt: De totale vergoeding ($USD 3.16M ) Eric } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 667.78K ).

Compensatie versus inkomsten: De vergoeding van Eric is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Eric Shaff (48 yo)

5.8yrs

Tenure

US$3,158,336

Compensatie

Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Eric Shaff	President	5.8yrs	US$3.16m	0.096% $ 113.1k
Lisa von Moltke	Executive VP & Chief Medical Officer	4.6yrs	US$1.57m	0.014% $ 16.3k
Teresa Young	Executive VP and Chief Commercial & Strategy Officer	4.3yrs	US$1.82m	0.053% $ 62.0k
Marella Thorell	Executive VP & CFO	less than a year	geen gegevens	geen gegevens
David Ege	Executive VP & Chief Technology Officer	4yrs	US$5.32m	0.051% $ 60.1k
Matthew Henn	Executive VP & Chief Scientific Officer	5.7yrs	US$1.67m	0.044% $ 52.1k
Carlo Tanzi	Investor Relations Officer	8.9yrs	geen gegevens	geen gegevens
Thomas DesRosier	Chief Legal Officer	8.4yrs	US$1.44m	0.082% $ 96.2k
Caroline Holda	Assistant General Counsel	no data	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MCRB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Eric Shaff	President	5.8yrs	US$3.16m	0.096% $ 113.1k
Willard Dere	Independent Director	7.3yrs	US$225.23k	0.021% $ 24.6k
Dennis Ausiello	Independent Director	9.5yrs	US$222.27k	0% $ 0
Kurt Graves	Independent Director	8.9yrs	US$219.23k	0% $ 0
Richard Kender	Independent Director	10yrs	US$232.69k	0.042% $ 49.2k
Mark Wilcox	Member of Scientific Advisory Board	9.8yrs	geen gegevens	geen gegevens
Andrew Goodman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Curtis Huttenhower	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Paul Biondi	Independent Director	4.6yrs	US$211.73k	0.031% $ 36.9k
Stephen Berenson	Independent Chairman	5.2yrs	US$249.23k	0.0024% $ 2.8k
Robert Jenq	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Elhanan Borenstein	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

8.1yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MCRB wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.1 jaar).

Seres Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Recent updates

Lucien Selce and MKT Capital Issue Open Letter to Board of Seres Therapeutics Regarding Reported Engagement with Nestlé

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Seres Therapeutics, Inc. Announces Topline Clinical Data from Cohort 2 of its SER-155 Phase 1b Placebo-Controlled Study in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

First half 2024 earnings released: US$0.49 loss per share (vs US$0.20 loss in 1H 2023)

Consensus EPS estimates upgraded to US$0.85 loss

Seres Therapeutics, Inc. announced that it expects to receive $15.000001 million in funding from Société des Produits Nestlé S.A.

Seres Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic

New minor risk - Market cap size

Price target decreased by 14% to US$6.20

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Consensus revenue estimates decrease by 63%, EPS upgraded

New minor risk - Financial position

Full year 2023 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Price target increased by 7.7% to US$9.02

Price target increased by 15% to US$9.80

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Forecast to breakeven in 2026

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Consensus EPS estimates upgraded to US$0.98 loss, revenue downgraded

Price target decreased by 13% to US$8.54

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Seres Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Consensus EPS estimates fall by 34%

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Second quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 7.6% to US$10.17

Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™

Consensus EPS estimates upgraded to US$0.96 loss

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.61 loss in 1Q 2022)

Consensus estimates of losses per share improve by 13%

Price target decreased by 11% to US$11.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics' Investigational Ser-109 Ecospor Iv Study Data Publishes in Jama Network Open

Seres Therapeutics, Inc. Announces Initiation of Enrollment in SER-155 Phase 1B Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Consensus forecasts updated

Price target increased to US$14.33

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Seres Therapeutics: The Good And The Challenging

Seres Therapeutics stock slips on $100M stock offering

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Seres Therapeutics, Inc. Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection At the Digestive Disease Week (Ddw) Annual Meeting